secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioStem Technologies, Inc. (BSEM)
CIK:        0001658678
Form:       8-K
Filed at:   2026-08-12T21:27:17+00:00
Accession:  0001193125-26-347211
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioStem Q2 revenue $7.9M (up 29% QoQ), net loss $9.0M, raises FY26 guide
------------------------------------------------------------------------

- Q2 2026 net revenue $7.9M vs $6.1M Q1 2026 (+29%) and $11.0M Q2 2025; hospital $6.7M, physician $1.1M.
- GAAP net loss $9.0M ($0.52/share) vs income $10,613 in Q2 2025; adjusted EBITDA loss $4.6M.
- Cash $7.0M at June 30, 2026 (from $13.7M); used $5.5M in ops; closed $2.5M private placement.
- Resolved $5.3M debt via $3.5M cash and $1.0M promissory note; uplisted to Nasdaq Capital Market Aug 7, 2026.
- Raises FY2026 revenue guidance to $26-29M from $25-29M; issued eight new U.S. design patents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658678/000119312526347211/0001193125-26-347211-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658678/000119312526347211/bsem-20260812.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-347211

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer